ArticleThe Lancet regional health. Western Pacific2026
Epidemiology and clinical characteristics of invasive group A streptococcal infection in the Republic of Korea, 2015-2024: a nationwide multicenter study.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive group A streptococcal (iGAS) infection has resurged globally following the coronavirus disease 2019 pandemic; however, long-term nationwide data from Asia is limited. This study aimed to investigate the epidemiology, clinical burden and molecular characteristics of iGAS infection in the Republic of Korea (ROK) over a 10-year period. Methods: A nationwide multicentre study for iGAS was conducted across 23 university-affiliated hospitals from 2015 to 2024. iGAS was defined as culture-confirmed isolation of Findings: A total of 454 iGAS cases were identified. The mean annual incidence was 4.72/100,000 admissions (95% CI 4.26-5.13), declining from 7.03 (95% CI 6.26-7.77) in 2015-2019 to 1.72 (95% CI 1.27-2.26) in 2020-2022. In 2023-2024, the incidence returned to pre-pandemic levels among children (10.45 per 100,000 admissions, 95% CI 5.95-14.39), whereas the adult incidence partially recovered (2.47 per 100,000 admissions, 95% CI 1.76-3.33). Skin and soft tissue infection (22.7%), streptococcal toxic shock syndrome (STSS, 19.6%), and bacteremia without focus (17.0%) were the most common iGAS infections. Intensive care unit admission was required in 28.9% of iGAS cases, and overall mortality was 15.5%. Mortality was independently associated with STSS (aOR 20.07, 95% CI 9.30-43.30; p < 0.0001), older age (aOR 20.07, 95% CI 9.30-43.30; p < 0.0001), chronic medical condition (aOR 2.96, 95% CI 1.41-6.22; p = 0.004), and immunocompromised condition (aOR 2.33, 95% CI 1.07-5.09; p = 0.034) among adults. Among 98 isolates, the predominant strains were Interpretation: Following marked pandemic-associated suppression, iGAS incidence rapidly rebounded among children in the ROK. This study reports the first detection of the M1UK lineage in the ROK, highlighting the need for statutory notification of iGAS as a nationally notifiable disease to enable continuous national surveillance with molecular characterization for monitoring emerging epidemic-prone strains. Funding: This work was supported by the Korea Disease Control and Prevention Agency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.